AN ACT TO REENACT SECTION 83-9-8.1, MISSISSIPPI CODE OF 1972, WHICH PROHIBITS A HEALTH BENEFIT PLAN FROM REQUIRING STEP THERAPY OR FAIL-FIRST PROTOCOLS BEFORE THE PLAN PROVIDES COVERAGE OF CERTAIN PRESCRIPTION DRUGS TO TREAT ADVANCED, METASTATIC CANCER AND ASSOCIATED CONDITIONS; TO REENACT SECTION 83-9-36, MISSISSIPPI CODE OF 1972, WHICH PRESCRIBES THE PROCESS BY WHICH A PRESCRIBING PRACTITIONER MAY REQUEST AN OVERRIDE OF AN INSURER'S RESTRICTION ON MEDICATION FOR USE BY A STEP THERAPY OR FAIL-FIRST PROTOCOL; TO AMEND REENACTED SECTIONS 83-9-8.1 AND 83-9-36, MISSISSIPPI CODE OF 1972, TO CODIFY AND EXTEND THE DATE OF THE REPEALER ON THOSE SECTIONS WHICH WAS ORIGINALLY ENACTED IN THE EFFECTIVE DATE SECTION OF THE ENABLING LEGISLATION; TO AMEND SECTION 3, CHAPTER 379, LAWS OF 2024, TO DELETE THE REPEALER ON SECTIONS 83-9-8.1 AND 83-9-36, MISSISSIPPI CODE OF 1972, FROM THE EFFECTIVE DATE SECTION OF THAT ACT; AND FOR RELATED PURPOSES.
Impact
If enacted, HB 944 would strengthen patient rights by codifying protections against health insurance practices that can impede access to crucial medications for cancer treatment. With the repeal of restrictions, the bill aims to streamline the approval process for necessary drugs, which is critical for patients whose conditions may deteriorate without timely treatment. Supporters argue that this measure will improve health outcomes for cancer patients, while also reducing administrative burdens on healthcare providers in securing the necessary medications for their patients.
Summary
House Bill 944 aims to reenact and amend certain provisions of the Mississippi Code that prohibit health benefit plans from imposing step therapy or fail-first protocols for covering prescription drugs for treating advanced, metastatic cancer and associated conditions. This legislation seeks to ensure that patients can access necessary medications without undergoing potentially ineffective treatments first, which could delay appropriate care. The bill emphasizes the importance of immediate access to drugs as recommended by their healthcare providers, recognizing the urgency often needed in treating advanced cancers.
Contention
Despite its supportive intentions, the bill may face opposition from some stakeholders within the health insurance industry who argue that step therapy protocols are an essential tool for managing healthcare costs. Critics of the bill may contend that removing these protocols could lead to increased healthcare expenditures by allowing potentially expensive drugs to be prescribed without prior authorization. Discussions surrounding the bill are likely to highlight the ongoing tension between healthcare access and cost-control measures within the insurance framework.